Literature DB >> 5690813

Mode of action of alanosine.

G R Gale, G B Schmidt.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1968        PMID: 5690813     DOI: 10.1016/0006-2952(68)90246-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  7 in total

1.  Some effects of atrazine on Ehrlich ascites tumor cells in vitro and in vivo.

Authors:  E M Walker; G R Gale; L M Atkins; R H Gadsden
Journal:  Bull Environ Contam Toxicol       Date:  1979-05       Impact factor: 2.151

2.  Some effects of dieldrin and mirex on Ehrlich ascites tumor cells in vivo and in vitro.

Authors:  E M Walker; G R Gale; L M Atkins; R H Gadsden
Journal:  Arch Environ Contam Toxicol       Date:  1977       Impact factor: 2.804

3.  EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.

Authors:  Ayse Batova; Howard Cottam; John Yu; Mitchell B Diccianni; Carlos J Carrera; Alice L Yu
Journal:  Blood       Date:  2005-10-18       Impact factor: 22.113

4.  Assignment of the gene for adenine phosphoribosyltransferase to human chromosome 16 by mouse-human somatic cell hybridization.

Authors:  J A Tischfield; F H Ruddle
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

5.  A new reduced human-mouse somatic cell hybrid containing the human gene for adenine phosphoribosyltransferase.

Authors:  T Kusano; C Long; H Green
Journal:  Proc Natl Acad Sci U S A       Date:  1971-01       Impact factor: 11.205

6.  Microbiological assay for estimating concentrations of DL-alanosine in mouse tissue.

Authors:  R F Pittillo; C Woolley
Journal:  Antimicrob Agents Chemother       Date:  1973-06       Impact factor: 5.191

7.  Contragestational profile of the tumor-inhibiting agent, L-alanosine, in the rat and the hamster.

Authors:  G Galliani; A Assandri; D Barone; M Grandi; G Mistrello; G C Lancini
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.